1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1053/ejpn.2000.0455" target="_blank" rel="noreferrer noopener">http://doi.org/​10.1053/ejpn.2000.0455</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses--a pilot study Publisher An entity responsible for making the resource available European Journal of Paediatric Neurology Date A point or period of time associated with an event in the lifecycle of the resource 2001 Subject The topic of the resource Adolescent; Adult; Antidepressive Agents; (Second-Generation) 0; (Antipsychotic Agents) 0; (Dibenzothiazepines) 0DHU5B8D6V; (Citalopram) 12794-10-4; (Benzodiazepines) 132539-06-1; (olanzapine) 2S3PL1B6UJ; (Quetiapine Fumarate) 3G0285N20N; (Pirenzepine) L6UH7ZF8HC; Risperidone; Second-Generation/ad [Administration & Dosage]; Antidepressive Agents; alertness; behavior; trajectory; characteristics; aggression Creator An entity primarily responsible for making the resource Backman M L; Aberg L E; Aronen E T; Santavuori P R Description An account of the resource Patients with juvenile neuronal ceroid lipofuscinosis (JNCL) often have severe psychiatric symptoms. These are common in their mid-teens and include such symptoms as anxiety and affective and psychotic disorders. The older antidepressants and antipsychotics do not seem to be effective and often cause many adverse effects. Therefore, we wanted to try the new psychotropic drugs in Finnish patients with JNCL. We also wanted to determine the profile of these drugs in this patient group. Fourteen Finnish patients with JNCL receiving psychotropic drug treatment with citalopram, risperidone, olanzapine or quetiapine, were included. The mean age at initiation of the new psychotropic drugs was 13.8 years. Indications for treatment were psychotic symptoms, affective symptoms, anxiety and an inadequate response to other psychotropic drugs, or even adverse reactions. Information on psychiatric symptoms and current treatment was gathered from interviews and from the medical records. Indications and the clinical outcome of the treatment were determined by a consensus of the assessments by parents and physicians. The psychotropic drugs most commonly used in Finnish patients with JNCL are citalopram and risperidone. The clinical outcome was good or satisfactory in 70%. The adverse effects most commonly reported were fatigue, weight gain and aggravation of extrapyramidal symptoms. Little research has been done in this area and there are no good guidelines for treatment of psychiatric symptoms in patients with JNCL. Therefore, every patient should be treated with the safest and most commonly used drugs in the lowest possible doses. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1053/ejpn.2000.0455" target="_blank" rel="noreferrer noopener">10.1053/ejpn.2000.0455</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). (Antipsychotic Agents) 0 (Benzodiazepines) 132539-06-1 (Citalopram) 12794-10-4 (Dibenzothiazepines) 0DHU5B8D6V (olanzapine) 2S3PL1B6UJ (Pirenzepine) L6UH7ZF8HC (Quetiapine Fumarate) 3G0285N20N (Second-Generation) 0 2001 Aberg L E Adolescent Adult Aggression alertness Antidepressive Agents Aronen E T Backman M L Behavior characteristics European Journal of Paediatric Neurology Risperidone Santavuori P R Second-Generation/ad [Administration & Dosage] Trajectory